Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 253

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research

Open access
Anglesio, Michael S., Wiegand, Kimberly C., Melnyk, Nataliya, Chow, Christine, Salamanca, Clara, Prentice, Leah M., Senz, Janine, Yang, Winnie, Spillman, Monique A., Cochrane, Dawn R., Shumansky, Karey, Shah, Sohrab P., Kalloger, Steve E., Huntsman, David G.·2013·PLoS ONE
DOI 10.1371/journal.pone.0072162
Open this paper in CoChat — free account

Abstract

BACKGROUND: OVARIAN CARCINOMAS CONSIST OF AT LEAST FIVE DISTINCT DISEASES: high-grade serous, low-grade serous, clear cell, endometrioid, and mucinous. Biomarker and molecular characterization may represent a more biologically relevant basis for grouping and treating this family of tumors, rather than site of origin. Molecular characteristics have become the new standard for clinical pathology, however development of tailored type-specific therapies is hampered by a failure of basic research to recognize that model systems used to study these diseases must also be stratified. Unrelated model systems do offer value for study of biochemical processes but specific cellular context needs to be applied to assess relevant therapeutic strategies. METHODS: We have focused on the identification of clear cell carcinoma cell line models. A panel of 32 "ovarian cancer" cell lines has been classified into histotypes using a combination of mutation profiles, IHC mutation-surrogates, and a validated immunohistochemical model. All cell lines were identity verified using STR analysis. RESULTS: Many described ovarian clear cell lines have characteristic mutations (including ARID1A and PIK3CA) and an overall molecular/immuno-profile typical of primary tumors. Mutations in TP53 were present in the majority of high-grade serous cell lines. Advanced genomic analysis of bona-fide clear cell carcinoma cell lines also support copy number changes in typical biomarkers such at MET and HNF1B and a lack of any recurrent expressed re-arrangements. CONCLUSIONS: As with primary ovarian tumors, mutation status of cancer genes like ARID1A and TP53 and a general immuno-profile serve well for establishing histotype of ovarian cancer cell We describe specific biomarkers and molecular features to re-classify generic "ovarian carcinoma" cell lines into type specific categories. Our data supports the use of prototype clear cell lines, such as TOV21G and JHOC-5, and questions the use of SKOV3 and A2780 as models of high-grade serous carcinoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0072162

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 88

  1. N Auersperg, 2011, The origin of ovarian carcinomas: a unifying hypothesis, Int J Gynecol Pathol, 30, 12, 10.1097/PGP.0b013e3181f45f3e · DOI
  2. SE Kalloger, 2011, Calculator for ovarian carcinoma subtype prediction, Mod Pathol, 24, 512, 10.1038/modpathol.2010.215 · DOI
  3. RA Soslow, 2008, Histologic subtypes of ovarian carcinoma: an overview, Int J Gynecol Pathol, 27, 161
  4. M Kobel, 2008, Ovarian carcinoma subtypes are different diseases: implications for biomarker studies, PLoS Med, 5, e232, 10.1371/journal.pmed.0050232 · DOI · Paper page
  5. MS Anglesio, 2008, Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors, Mol Cancer Res, 6, 1678, 10.1158/1541-7786.MCR-08-0193 · DOI
  6. RW Tothill, 2008, Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome, Clin Cancer Res, 14, 5198, 10.1158/1078-0432.CCR-08-0196 · DOI · Paper page
  7. RJ Kurman, 2011, Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-Shifting the paradigm, Hum Pathol, 42, 918, 10.1016/j.humpath.2011.03.003 · DOI · Paper page
  8. RJ Kurman, 2010, The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory, Am J Surg Pathol, 34, 433, 10.1097/PAS.0b013e3181cf3d79 · DOI · Paper page
  9. Network The Cancer Genome Atlas Research, 2011, Integrated genomic analyses of ovarian carcinoma, Nature, 474, 609, 10.1038/nature10166 · DOI · Paper page
  10. WG McCluggage, 2011, Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis, Pathology, 43, 420, 10.1097/PAT.0b013e328348a6e7 · DOI · Paper page
  11. K Levanon, 2010, Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis, Oncogene, 29, 1103, 10.1038/onc.2009.402 · DOI · Paper page
  12. JW Carlson, 2010, Serous tubal intraepithelial carcinoma: diagnostic reproducibility and its implications, Int J Gynecol Pathol, 29, 310, 10.1097/PGP.0b013e3181c713a8 · doi:10.1097/pgp.0b013e3181c713a8
  13. CP Crum, 2007, Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer, Clin Med Res, 5, 35, 10.3121/cmr.2007.702 · DOI · Paper page
  14. AR Laury, 2011, Fallopian tube correlates of ovarian serous borderline tumors, Am J Surg Pathol, 35, 1759, 10.1097/PAS.0b013e318233b0f7 · doi:10.1097/pas.0b013e318233b0f7
  15. MS Anglesio, 2011, Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010, Gynecol Oncol, 121, 407, 10.1016/j.ygyno.2011.01.005 · DOI · Paper page
  16. KM Feeley, 2001, Precursor lesions of ovarian epithelial malignancy, Histopathology, 38, 87, 10.1046/j.1365-2559.2001.01042.x · DOI · Paper page
  17. EJ Thomas, 2000, Evidence that endometriosis behaves in a malignant manner, Gynecol Obstet Invest, 50, 2, 10.1159/000052872 · DOI
  18. EJ Thomas, 2000, Molecular genetic defects in endometriosis, Gynecol Obstet Invest, 50, 44, 10.1159/000052878 · DOI
  19. AH Prowse, 2006, Molecular genetic evidence that endometriosis is a precursor of ovarian cancer, Int J Cancer, 119, 556, 10.1002/ijc.21845 · DOI · Paper page
  20. Schiavone MB, Herzog TJ, Lewin SN, Deutsch I, Sun X, <etal>et al</etal>.. (2011) Natural history and outcome of mucinous carcinoma of the ovary. Am J Obstet Gynecol 205: 480 e481–488. · doi:10.1016/j.ajog.2011.06.049
  21. MS Anglesio, 2013, Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas, J Pathol, 229, 111, 10.1002/path.4088 · DOI · Paper page
  22. V Hess, 2004, Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment, J Clin Oncol, 22, 1040, 10.1200/JCO.2004.08.078 · DOI · Paper page
  23. EM Berns, 2012, The changing view of high-grade serous ovarian cancer, Cancer Res, 72, 2701, 10.1158/0008-5472.CAN-11-3911 · DOI · Paper page
  24. S Vaughan, 2011, Rethinking ovarian cancer: recommendations for improving outcomes, Nat Rev Cancer, 11, 719, 10.1038/nrc3144 · DOI · Paper page
  25. JN McAlpine, 2012, BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma, Mod Pathol, 25, 740, 10.1038/modpathol.2011.211 · DOI · Paper page
  26. HA Risch, 2006, Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada, J Natl Cancer Inst, 98, 1694, 10.1093/jnci/djj465 · DOI · Paper page
  27. K Alsop, 2012, BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group, J Clin Oncol, 30, 2654, 10.1200/JCO.2011.39.8545 · DOI · Paper page
  28. JT Quirk, 2005, Ovarian cancer incidence in the United States, 1992–1999, Gynecol Oncol, 97, 519, 10.1016/j.ygyno.2005.02.007 · DOI · Paper page
  29. V McGuire, 2002, Survival among U.S. women with invasive epithelial ovarian cancer, Gynecol Oncol, 84, 399, 10.1006/gyno.2001.6536 · DOI
  30. DM Gershenson, 2012, Treatment of ovarian cancer in young women, Clin Obstet Gynecol, 55, 65, 10.1097/GRF.0b013e318248045b · DOI
  31. C Korch, 2012, DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination, Gynecol Oncol, 127, 241, 10.1016/j.ygyno.2012.06.017 · DOI · Paper page
  32. Kommoss S, Gilks CB, Kommoss F, Anglesio MS, Chow C, <etal>et al</etal>.. (2013) Accelerating type-specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (COSP) is a reliable high-throughput tool for case review. Histopathology (accepted June 2, 2013). · doi:10.1111/his.12219
  33. FI Lu, 2012, Prevalence of loss of expression of DNA mismatch repair proteins in primary epithelial ovarian tumors, Int J Gynecol Pathol, 31, 524, 10.1097/PGP.0b013e31824fe2aa · DOI
  34. VA Malkov, 2009, Multiplexed measurements of gene signatures in different analytes using the Nanostring nCounter Assay System, BMC Res Notes, 2, 80, 10.1186/1756-0500-2-80 · DOI · Paper page
  35. MK McConechy, 2012, Use of mutation profiles to refine the classification of endometrial carcinomas, J Pathol, 228, 20, 10.1002/path.4056 · DOI · Paper page
  36. SA Forbes, 2011, COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer, Nucleic Acids Res, 39, D945, 10.1093/nar/gkq929 · DOI · Paper page
  37. M Kobel, 2011, Biomarker expression in pelvic high-grade serous carcinoma: comparison of ovarian and omental sites, Int J Gynecol Pathol, 30, 366, 10.1097/PGP.0b013e31820d20ba · doi:10.1097/pgp.0b013e31820d20ba
  38. M Kobel, 2010, The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas, J Pathol, 222, 191, 10.1002/path.2744 · DOI · Paper page
  39. JN McAlpine, 2009, HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy, BMC Cancer, 9, 433, 10.1186/1471-2407-9-433 · DOI · Paper page
  40. M Kobel, 2009, A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary, Am J Surg Pathol, 33, 14, 10.1097/PAS.0b013e3181788546 · DOI · Paper page
  41. S Jones, 2010, Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma, Science, 330, 228, 10.1126/science.1196333 · DOI · Paper page
  42. P Taverna, 2000, Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen, Cancer Chemother Pharmacol, 46, 507, 10.1007/s002800000186 · DOI
  43. CT Warnick, 2001, Identification of a p53 response element in the promoter region of the hMSH2 gene required for expression in A2780 ovarian cancer cells, J Biol Chem, 276, 27363, 10.1074/jbc.M103088200 · DOI
  44. IG Campbell, 2004, Mutation of the PIK3CA gene in ovarian and breast cancer, Cancer Res, 64, 7678, 10.1158/0008-5472.CAN-04-2933 · DOI · Paper page
  45. KT Kuo, 2009, Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma, Am J Pathol, 174, 1597, 10.2353/ajpath.2009.081000 · DOI · Paper page
  46. A Hirasawa, 2003, Association of 17q21–q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets, Clin Cancer Res, 9, 1995
  47. DS Tan, 2009, PPM1D is a potential therapeutic target in ovarian clear cell carcinomas, Clin Cancer Res, 15, 2269, 10.1158/1078-0432.CCR-08-2403 · DOI · Paper page
  48. DS Tan, 2011, Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas, Clin Cancer Res, 17, 1521, 10.1158/1078-0432.CCR-10-1688 · DOI
  49. MS Anglesio, 2011, IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer, Clin Cancer Res, 17, 2538, 10.1158/1078-0432.CCR-10-3314 · DOI · Paper page
  50. Spowart JE, Townsend KN, Huwait H, Eshragh S, West NR, <etal>et al</etal>.. (2012) The Autophagy Protein LC3A Correlates with Hypoxia and is a Prognostic Marker of Patient Survival in Clear Cell Ovarian Cancer. J Pathol. · DOI
  51. MT Rahman, 2012, Prognostic and therapeutic impact of the chromosome 20q13.2 ZNF217 locus amplification in ovarian clear cell carcinoma, Cancer, 118, 2846, 10.1002/cncr.26598 · DOI
  52. S Yamamoto, 2011, Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient, Mod Pathol, 24, 1146, 10.1038/modpathol.2011.70 · DOI
  53. S Yamamoto, 2012, Accumulative copy number increase of MET drives tumor development and histological progression in a subset of ovarian clear-cell adenocarcinomas, Mod Pathol, 25, 122, 10.1038/modpathol.2011.143 · DOI
  54. KT Kuo, 2010, DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma, Clin Cancer Res, 16, 1997, 10.1158/1078-0432.CCR-09-2105 · DOI
  55. X Zhang, 2011, The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene, Oncogene, 30, 2810, 10.1038/onc.2011.8 · DOI · Paper page
  56. JJ Wei, 2011, Endometriosis and ovarian cancer: a review of clinical, pathologic, and molecular aspects, International journal of gynecological pathology: official journal of the International Society of Gynecological Pathologists, 30, 553, 10.1097/PGP.0b013e31821f4b85 · DOI · Paper page
  57. A LaGrenade, 1988, Ovarian tumors associated with atypical endometriosis, Hum Pathol, 19, 1080, 10.1016/S0046-8177(88)80090-X · DOI · Paper page
  58. K Razzouk, 2007, Mixed clear cell and endometrioid carcinoma arising in parietal endometriosis, Gynecol Obstet Invest, 63, 140, 10.1159/000096437 · DOI
  59. PJ DiSaia, 1972, Cell-mediated immunity to human malignant cells. A brief review and further studies with two gynecologic tumors, Am J Obstet Gynecol, 114, 979, 10.1016/0002-9378(72)90109-3 · DOI
  60. TJ Shaw, 2004, Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer, Mol Ther, 10, 1032, 10.1016/j.ymthe.2004.08.013 · DOI · Paper page
  61. J Madore, 2010, Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma, J Pathol, 220, 392, 10.1002/path.2659 · DOI
  62. Farley JH, Brady WE, Birrer MJ, Lankes H, Coleman R, <etal>et al</etal>.. (2012) A phase II trial of selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum. AACR Annual Meeting 2012, Chicogo, IL, USA. · doi:10.1158/1538-7445.am2012-ct-05
  63. Altman AD, Nelson GS, Ghatage P, McIntyre JB, Capper D, <etal>et al</etal>.. (2013) The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors. Mod Pathol. · DOI
  64. I Danjoh, 2013, Dominant expansion of a cryptic subclone with an abnormal karyotype in B lymphoblastoid cell lines during culture, Cytogenet Genome Res, 139, 88, 10.1159/000343757 · DOI
  65. KQ Cai, 2004, Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma, Hum Pathol, 35, 552, 10.1016/j.humpath.2003.12.009 · DOI
  66. J Liu, 2004, Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer, Mod Pathol, 17, 75, 10.1038/modpathol.3800017 · DOI
  67. K Domanska, 2007, Ovarian cancer at young age: the contribution of mismatch-repair defects in a population-based series of epithelial ovarian cancer before age 40, Int J Gynecol Cancer, 17, 789, 10.1111/j.1525-1438.2007.00875.x · DOI
  68. KC Jensen, 2008, Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger, Am J Surg Pathol, 32, 1029, 10.1097/PAS.0b013e31816380c4 · DOI
  69. E Hernandez, 1984, Interobserver variability in the interpretation of epithelial ovarian cancer, Gynecol Oncol, 17, 117, 10.1016/0090-8258(84)90065-9 · doi:10.1016/0090-8258(84)90065-9
  70. A Sakamoto, 1994, Observer disagreement in histological classification of ovarian tumors in Japan, Gynecol Oncol, 54, 54, 10.1006/gyno.1994.1165 · doi:10.1006/gyno.1994.1165
  71. SF Cramer, 1987, Evaluation of the reproducibility of the World Health Organization classification of common ovarian cancers. With emphasis on methodology, Arch Pathol Lab Med, 111, 819
  72. KD Swenerton, 2011, Histotype predicts the curative potential of radiotherapy: the example of ovarian cancers, Ann Oncol, 22, 341, 10.1093/annonc/mdq383 · DOI
  73. SM Hunter, 2011, Copy number aberrations in benign serous ovarian tumors: a case for reclassification?, Clin Cancer Res, 17, 7273, 10.1158/1078-0432.CCR-11-2080 · DOI
  74. M Kobel, 2010, Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications, Gynecol Oncol, 116, 50, 10.1016/j.ygyno.2009.09.029 · DOI
  75. M Kobel, 2010, Differences in tumor type in low-stage versus high-stage ovarian carcinomas, Int J Gynecol Pathol, 29, 203, 10.1097/PGP.0b013e3181c042b6 · DOI · Paper page
  76. M Kobel, 2010, Diagnosis of ovarian carcinoma cell type is highly reproducible: a transcanadian study, Am J Surg Pathol, 34, 984, 10.1097/PAS.0b013e3181e1a3bb · DOI
  77. CB Gilks, 2008, Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma, Hum Pathol, 39, 1239, 10.1016/j.humpath.2008.01.003 · DOI · Paper page
  78. IG Campbell, 2001, Endometriosis: candidate genes, Hum Reprod Update, 7, 15, 10.1093/humupd/7.1.15 · DOI
  79. JD Seidman, 2008, Exploring the histogenesis of ovarian mucinous and transitional cell (Brenner) neoplasms and their relationship with Walthard cell nests: a study of 120 tumors, Arch Pathol Lab Med, 132, 1753, 10.5858/132.11.1753 · DOI · Paper page
  80. CP Crum, 2009, Intercepting pelvic cancer in the distal fallopian tube: theories and realities, Mol Oncol, 3, 165, 10.1016/j.molonc.2009.01.004 · DOI · Paper page
  81. AA Ahmed, 2010, Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary, J Pathol, 221, 49, 10.1002/path.2696 · DOI · Paper page
  82. PA Shaw, 2002, Histopathologic features of genetically determined ovarian cancer, Int J Gynecol Pathol, 21, 407, 10.1097/00004347-200210000-00011 · DOI
  83. McBride DJ, Etemadmoghadam D, Cooke SL, Alsop K, George J, <etal>et al</etal>.. (2012) Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes. J Pathol. · DOI
  84. LR Duska, 2010, When ‘never-events’ occur despite adherence to clinical guidelines: the case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes, Gynecol Oncol, 116, 374, 10.1016/j.ygyno.2009.10.069 · DOI
  85. HJ Mackay, 2010, Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer, Int J Gynecol Cancer, 20, 945, 10.1111/IGC.0b013e3181dd0110 · DOI · Paper page
  86. DJ Storey, 2008, Endometrioid epithelial ovarian cancer: 20 years of prospectively collected data from a single center, Cancer, 112, 2211, 10.1002/cncr.23438 · DOI
  87. KM Schmeler, 2008, Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum, Gynecol Oncol, 108, 510, 10.1016/j.ygyno.2007.11.013 · DOI · Paper page
  88. R Vang, 2009, Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems, Advances in anatomic pathology, 16, 267, 10.1097/PAP.0b013e3181b4fffa · DOI · Paper page

Cited by

See all 253

Metadata

Authors
Anglesio, M. S., Wiegand, K. C., Melnyk, N., Chow, C., Salamanca, C., Prentice, L. M., Senz, J., Yang, W., Spillman, M. A., Cochrane, D. R., Shumansky, K., Shah, S. P., Kalloger, S. E., & Huntsman, D. G.
Venue
PLoS ONE
Publisher
Public Library of Science (PLoS)
Published
2013-09-04
Volume
8
Issue
9
Pages
e72162
ISSN
1932-6203 (ISSN-L)
DOI
10.1371/journal.pone.0072162
OpenAlex
W2025669441
Cited by
253
References
4
FWCI
23.70
Type
journal article
Language
en
Update notices
Open access
gold
Licence
creativecommons.org/licenses/by/4.0/ (unspecified)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research. https://app.cochat.ai/papers/10.1371/journal.pone.0072162
The paper
Anglesio, M. S., Wiegand, K. C., Melnyk, N., Chow, C., Salamanca, C., Prentice, L. M., Senz, J., Yang, W., Spillman, M. A., Cochrane, D. R., Shumansky, K., Shah, S. P., Kalloger, S. E., & Huntsman, D. G. (2013). Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research. PLoS ONE. https://doi.org/10.1371/journal.pone.0072162

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.